BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37218357)

  • 1. Editorial Comment on "Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma".
    Teishima J
    Int J Urol; 2023 Sep; 30(9):752-753. PubMed ID: 37218357
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Yoshino M; Ishihara H; Nemoto Y; Nakamura K; Nishimura K; Tachibana H; Fukuda H; Toki D; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Jpn J Clin Oncol; 2022 Oct; 52(10):1208-1214. PubMed ID: 35780441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma.
    Hara T; Furukawa J; Shiraishi Y; Okamura Y; Bando Y; Terakawa T; Harada K; Nakano Y; Fujisawa M
    Int J Urol; 2023 Sep; 30(9):746-752. PubMed ID: 37130778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
    Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
    Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma.
    Shirotake S; Miyama YU; Baba Y; Tajima H; Okada Y; Nakazawa K; Usami Y; Yasuda M; Igarashi D; Kaneko GO; Kanao K; Oyama M; Nishimoto K
    Anticancer Res; 2022 May; 42(5):2727-2735. PubMed ID: 35489743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report.
    Furubayashi N; Taguchi K; Negishi T; Miura A; Sato Y; Miyoshi M; Nakamura M
    In Vivo; 2022; 36(1):510-521. PubMed ID: 34972756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
    Kim HL; Mayerson E; Lara PN; Messing E; Tangen C; Shuch BM; Vaishampayan U
    Eur Urol Focus; 2019 Nov; 5(6):927-929. PubMed ID: 31103605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
    Kato T; Fujita K; Minami T; Nagahara A; Hyashi Y; Nakata W; Matsuzaki K; Nakano K; Hatano K; Kawashima A; Imamura R; Takada S; Nishimura K; Tsujihata M; Takao T; Nakai Y; Nakayama M; Nishimura K; Uemura M; Uemura H; Nonomura N
    Int J Clin Oncol; 2022 Oct; 27(10):1596-1604. PubMed ID: 35831538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study.
    Ishihara H; Takagi T; Yoshida K; Hashimoto Y; Kondo T; Tanabe K
    Int J Urol; 2021 Oct; 28(10):1075-1076. PubMed ID: 34218475
    [No Abstract]   [Full Text] [Related]  

  • 10. [Deep and Durable Response After Discontinuation of Nivolumab/Ipilimumab Combination Therapy for Metastatic Renal Cell Carcinoma : A Case Report].
    Tsuruta M; Shibasaki N; Iguch R; Yamaguchi T; Ota H; Fuchigami Y; Magaribuchi T; Naito H; Terai A
    Hinyokika Kiyo; 2020 Dec; 66(12):443-448. PubMed ID: 33435655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
    Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation.
    Schvartsman G; Carneiro APCD; Filippi RZ; Rao P; Msaouel P
    Clin Genitourin Cancer; 2019 Aug; 17(4):315-318. PubMed ID: 31213412
    [No Abstract]   [Full Text] [Related]  

  • 13. Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.
    Kobayashi Y; Arai H; Honda M
    Curr Oncol; 2020 Aug; 27(4):225-228. PubMed ID: 32905370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of prognostic prediction by early assessment of response to combined treatment with nivolumab plus ipilimumab in patients with treatment-naïve metastatic renal cell carcinoma.
    Harada KI; Miyake H; Furukawa J; Fujimoto N; Fujisawa M
    Int J Urol; 2023 Sep; 30(9):798-800. PubMed ID: 36722291
    [No Abstract]   [Full Text] [Related]  

  • 15. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
    Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
    Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
    Motzer RJ; Russo P; Grünwald V; Tomita Y; Zurawski B; Parikh O; Buti S; Barthélémy P; Goh JC; Ye D; Lingua A; Lattouf JB; Albigès L; George S; Shuch B; Sosman J; Staehler M; Vázquez Estévez S; Simsek B; Spiridigliozzi J; Chudnovsky A; Bex A
    Target Oncol; 2023 Sep; 18(5):639-641. PubMed ID: 37659025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.
    Kikuchi H; Osawa T; Matsumoto R; Abe T; Maruyama S; Harabayashi T; Miyata H; Kashiwagi A; Ikeshiro S; Sazawa A; Fukui R; Morita K; Takeuchi I; Hori K; Yamashita N; Minami K; Mochizuki T; Murai S; Shinohara N
    Urol Oncol; 2022 Jan; 40(1):13.e19-13.e27. PubMed ID: 34716079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inferior vena cava thrombectomy following complete response to nivolumab/ipilimumab for metastatic renal cell carcinoma.
    Shepherd ARH; Joshi R; Tan CP; Cohen P; Brook NR
    ANZ J Surg; 2020 Jul; 90(7-8):1517-1519. PubMed ID: 31833177
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.
    Bando Y; Furukawa J; Okamura Y; Hara T; Terakawa T; Nakano Y; Fujisawa M
    Anticancer Res; 2022 Feb; 42(2):973-979. PubMed ID: 35093897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study).
    Kojima T; Kato R; Sazuka T; Yamamoto H; Fukuda S; Yamana K; Nakaigawa N; Sugino Y; Hamamoto S; Ito H; Murakami H; Obara W
    Jpn J Clin Oncol; 2022 Nov; 52(11):1345-1352. PubMed ID: 35920793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.